Skip to main content
Premium Trial:

Request an Annual Quote

Susan Siegel, Carl Balezentis, Rob Martienssen, Peter Leddy, and SoftGenetics



Affymetrix disclosed Susan Siegel's compensation package as president emeritus in documents filed with the Securities and Exchange Commission last week.

Siegel resigned as president of the company in April.

In her new position, Siegel will receive an annual base salary of $426,315. If her employment ends before Nov. 19, 2007, she will receive a cash payment equal to $675,000 less the salary she received starting April 19. In addition, her health coverage will last until Oct. 19, 2007. Her stock options will continue its accelerated vesting as if she'd remained with the company until that date.

Enzo Biochem appointed Carl Balezentis as president of Enzo Life Sciences, its wholly owned subsidiary, the company said this week.

Formerly, Balezentis was chief executive officer of Lark Technologies prior to its acquisition by Genaissance Pharmaceuticals. After the acquisition, he joined Genaissance as a senior vice president. Prior to Lark, he was director of business development at Sigma-Aldrich's life sciences division. He was vice president of sales and marketing at Genosys Biotechnologies prior to its acquisition by Sigma-Aldrich.

Balezentis was a director of marketing at Perceptive Scientific Instruments before its acquisition by International Remote Imaging Systems, and a group leader for human identity products at Applied Biosystems.

Orion Genomics co-founder Rob Martienssen has been appointed a fellow of the Royal Society of London, Orion said this week.

Past fellows include Isaac Newton, Charles Darwin, Albert Einstein, and James Watson, Orion said. Watson, like Martienssen, is also a member of Orion's scientific advisory board.

Martienssen holds a BA in natural sciences from Cambridge University and a PhD from the Plant Breeding Institute and Cambridge University.

He currently serves on the faculty at Cold Spring Harbor Laboratory.

The Biotechnology Institute named Invitrogen's Peter Leddy to its board of directors, the organization said last week.

Leddy is senior vice-president of human resources, a position he's held since July 2005. Prior to Invitrogen, Leddy spent five years with Dell in several management positions, most recently vice-president of human resources for Americas Operations.

He received his BA in psychology from Creighton University and his MS and PhD in industrial/organizational psychology from the Illinois Institute of Technology.


New Releases

SoftGenetics this week launched the latest version of its Mutation Surveyor software product for the detection of DNA variants from sequence traces. Version 3.0 includes enhancements to raw data processing to correct for poor early sequence mobility — which is an issue with some capillary sequencing systems, SoftGenetics said. The new version also includes: an automated methylation detection application; enhanced Het-Indel detecion algorithms; heterozygote and methylation quantification; and intelligent base-call editing, the company said.


Filed under

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.